Hangzhou Neoantigen Biotechnology co., LTD. announced that it has received $3,100,000 in a round of funding led by Betta Pharmaceuticals Co., Ltd. on September 17, 2021. The transaction also included participation from Shenzhen Dachen Caizhi Venture Capital Management Co., Ltd.